Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 401–500 of 1,007
RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt Pathway
Wang, F., Yamauchi, M., Muramatsu, M., Osawa, T., Tsuchida, R., & Shibuya, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165605 · Cited by 114
Pisanti, S., Borselli, C., Oliviero, O., Laezza, C., Gazzerro, P., & Bifulco, M. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20954 · Cited by 108
“Among these factors, vascular endothelial growth factor (VEGF), a soluble angiogenic factor produced by both normal and tumor cells, plays a key role in regulating normal and abnormal angiogenesis (Ferrara and Kerbel, 2005).”
BackgroundVasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis
Hosaka, T., Kimura, H., Heishi, T., Suzuki, Y., Miyashita, H., Ohta, H., Sonoda, H., Moriya, T., Suzuki, S., Kondo, T., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080788 · Cited by 107
“The most important molecule that stimulates angiogenesis is vascular endothelial growth factor (VEGF).(4) The circulating level of VEGF before treatment predicts the survival of patients with NSCLC.”
BackgroundTee, A. E., Liu, B., Song, R., Li, J., Pasquier, E., Cheung, B. B., Jiang, C., Marshall, G. M., Haber, M., Norris, M. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6675 · Cited by 108
Dai, L., Cui, X., Zhang, X., Cheng, L., Liu, Y., Yang, Y., Fan, P., Wang, Q., Lin, Y., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11996 · Cited by 107
RetractedGold nanoparticles for regulation of cell function and behavior
Bodelón, G., Costas, C., Pérez‐Juste, J., Pastoriza‐Santos, I., & Liz‐Marzán, L. M. (2017) · Nano Today · doi:10.1016/j.nantod.2016.12.014 · Cited by 111
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
Reiberger, T., Angermayr, B., Schwabl, P., Rohr‐Udilova, N., Mitterhauser, M., Gangl, A., & Peck‐Radosavljevic, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.06.024 · Cited by 107
“Its downregulation, together with the decreased expression of PDGF and aSMA under sorafenib treatment, could inhibit vascular maturation and remodeling in the splanchnic territory of PHT animals.”
BackgroundInfluentialBcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth
Kaneko, T., Zhang, Z., Mantellini, M. G., Karl, E., Zeitlin, B. D., Verhaegen, M. E., Soengas, M. S., Lingen, M. W., Strieter, R. M., Núñez, G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1497 · Cited by 108
“Selective elimination of tumor-associated endothelial cells is the goal of antiangiogenic therapeutic strategies that are being used today for the treatment of cancer (2, 3).”
BackgroundAngiogenesis and expression of PDGF ‐ C , VEGF , CD 105 and HIF ‐1α in human glioblastoma
Clara, C., Marie, S. K. N., Almeida, J. R. W., Wakamatsu, A., Oba‐Shinjo, S. M., Uno, M., Neville, M. A., & Rosemberg, S. (2014) · Neuropathology · doi:10.1111/neup.12111 · Cited by 112
“Moreover, targeting the vascular system as an anti-cancer strategy has been shown to have therapeutic efficacy.(3) Nonetheless, the response to anti-angiogenic therapies has not been”
BackgroundThe emerging roles of macrophages in cancer metastasis and response to chemotherapy
Sanchez, L. R., Borriello, L., Entenberg, D. R., Condeelis, J. S., Oktay, M. H., & Karagiannis, G. S. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0218-056rr · Cited by 114
Gerber, H., Wu, X., Yu, L., Wiesmann, C., Liang, X. H., Lee, C. V., Fuh, G., Olsson, C., Damico, L. A., Xie, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611492104 · Cited by 118
Self-citationRole of haematopoietic cells and endothelial progenitors in tumour angiogenesis
Palma, M. D., & Naldini, L. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.003 · Cited by 116
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Singh, M., & Ferrara, N. (2012) · Nature Biotechnology · doi:10.1038/nbt.2286 · Cited by 115
Self-citationAnticalin® Proteins as Therapeutic Agents in Human Diseases
Rothe, C., & Skerra, A. (2018) · BioDrugs · doi:10.1007/s40259-018-0278-1 · Cited by 118
“The first Tlc-derived Anticalin protein with prospects for therapeutic application was selected against human vascular endothelial growth factor (VEGF)-A, a key factor of tumor angiogenesis and ocular diseases [28].”
BackgroundEyeing central neurons in vascular growth and reparative angiogenesis
Sapieha, P. (2012) · Blood · doi:10.1182/blood-2012-04-396846 · Cited by 106
Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
Mackey, J. R., Kerbel, R. S., Gelmon, K. A., McLeod, D., Chia, S., Rayson, D., Verma, S., Collins, L. L., Paterson, A. H. G., Robidoux, A., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.002 · Cited by 115
Self-citationIntravoxel incoherent motion MRI as a means to measure in vivo perfusion: A review of the evidence
Federau, C. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3780 · Cited by 117
Gebauer, M., & Skerra, A. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00007-0 · Cited by 104
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
Sherman, S. I. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0923 · Cited by 105
Vascular tube formation and angiogenesis induced by polyvinylpyrrolidone-coated silver nanoparticles
Kang, K., Lim, D.-H., Choi, I., Kang, T., Lee, K., Moon, E.-Y., Yang, Y. D., Lee, M.-S., & Lim, J. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.05.1033 · Cited by 104
Yang, M., Reynoso, J., Bouvet, M., & Hoffman, R. M. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21999 · Cited by 107
Koo, B.-H., Coe, D. M., Dixon, L. J., Somerville, R. P. T., Nelson, C. M., Wang, L. W., Young, M. E., Lindner, D. J., & Apte, S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090655 · Cited by 116
“Following de novo formation of the vasculature from undifferentiated mesodermal precursors during embryogenesis (vasculogenesis), endothelial cells (ECs) proliferate and migrate to generate new capillaries from pre-existing blood vessels, a process termed angiogenesis.(1,2) Angiogenesis is critical for embryonic devel…”
BackgroundRoles of sphingosine-1-phosphate signaling in angiogenesis
Takuwa, Y., Du, W., 戚勋, Okamoto, Y., Takuwa, N., & Yoshioka, K. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i10.298 · Cited by 108
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ruan, J., Hajjar, K. A., Rafii, S., & Leonard, J. P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn666 · Cited by 115
“In contrast to the conventional ‘maximum tolerated dose’ (MTD) chemotherapy, metronomic chemotherapy refers to the administration of low doses of medications on a frequent or continuous schedule without extended drug-free breaks [20, 91].”
BackgroundKoch, U., Krause, M., & Baumann, M. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.003 · Cited by 112
Engineered 3D hydrogels with full-length fibronectin that sequester and present growth factors
Trujillo, S., Gonzalez-Garcia, C., Rico, P., Reid, A., Windmill, J., Dalby, M. J., & Salmeron-Sanchez, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120104 · Cited by 95
“During vasculogenesis, endothelial cells are highly dynamic and come together to form primitive capillary structures [80].”
BackgroundHypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings
Fraga, A. M., Ribeiro, R. J. T., Príncipe, P., Lopes, C., & Medeiros, R. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.03.006 · Cited by 111
Inhibition of tumor cell migration and metastasis by the proton-sensing GPR4 receptor
Castellone, R. D., Leffler, N. R., Dong, L., & Yang, L. V. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.013 · Cited by 114
“Molecular pathways related to hypoxia have served as targets for cancer treatment and diagnosis, such as VEGF and its receptors for anti-angiogenesis therapy and glucose transporters for FDG positron emission tomography [6,7].”
BackgroundRodrigues, E. G., Dobroff, A. S., Cavarsan, C. F., Paschoalin, T., Nimrichter, L., Mortara, R. A., dos Santos, E. L., Fázio, M. A., Miranda, A., Daffre, S., et al. (2008) · Neoplasia · doi:10.1593/neo.07885 · Cited by 106
“Emerging evidence, however, shows that tumors can also develop resistance to angiogenesis inhibitors [5].”
BackgroundDønnem, T., Al‐Saad, S., Al-Shibli, K. I., Delghandi, M. P., Persson, M., Nilsen, M. N., Busund, L., & Bremnes, R. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0414 · Cited by 112
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis
Strijkers, G. J., Kluza, E., van Tilborg, G. A. F., van der Schaft, D. W. J., Griffioen, A. W., Mulder, W. J. M., & Nicolay, K. (2010) · Angiogenesis · doi:10.1007/s10456-010-9165-1 · Cited by 107
“Inhibition of tumor angiogenesis is a modern and popular approach to fight tumor progression [1, 2].”
BackgroundThe function and mechanisms of action of LOXL2 in cancer (Review)
Wu, L., & Zhu, Y. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2337 · Cited by 113
“Angiogenesis contributes to primary and metastatic cancer growth, and it is necessary for tumor progression (37,38).”
The role of integrins in tumor angiogenesis
Hwang, R. F., & Varner, J. A. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.09.010 · Cited by 113
Manickam, V., Tiwari, A., Jung, J.-J., Bhattacharya, R., Goel, A., Mukhopadhyay, D., & Choudhury, A. (2010) · Blood · doi:10.1182/blood-2010-06-291690 · Cited by 111
Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody
Hernández, J. L., Padilla, L., Plaza, S. D., Coll, T., Hervas, R., Adán, J., Masa, M., Mitjans, F., Martinez, J. M., Coma, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072480 · Cited by 112
Haase, H. S., Peterson-Kaufman, K. J., Lan Levengood, S. K., Checco, J. W., Murphy, W. L., & Gellman, S. H. (2012) · Journal of the American Chemical Society · doi:10.1021/ja302469a · Cited by 100
Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den Meiracker, A. H. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5244 · Cited by 110
“VEGF is mainly upregulated by hypoxia-inducible factor 1 a , but various other factors are also involved (18, 19).”
Hydrogel-based flexible materials for diabetes diagnosis, treatment, and management
Jiang, S., Zhang, Y., Chan, S. Y., Du, Z., Yan, Y., Wang, T., Li, P., & Huang, W. (2021) · npj Flexible Electronics · doi:10.1038/s41528-021-00122-y · Cited by 110
Zhang, Y., Li, Q., Wang, J., Cheng, F., Huang, X., Cheng, Y., & Wang, K. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.037 · Cited by 102
Angiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal Medicine
Seto, S. W., Chang, D., Jenkins, A., Bensoussan, A., & Kiat, H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5060056 · Cited by 108
“Indeed, benefits of therapeutic angiogenesis (a clinical term referring to the enhancement of vessels growth in ischemic tissue) induced by direct injections or gene transfer of angiogenic factors have been demonstrated in myocardial infarction and limb ischemic injury [8].”
BackgroundNew insights into the autotaxin/LPA axis in cancer development and metastasis
Leblanc, R., & Peyruchaud, O. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.11.010 · Cited by 99
Principles and Therapeutic Implications of Angiogenesis, Vasculogenesis and Arteriogenesis
Fischer, C., Schneider, M., & Carmeliet, P. (2006) · Springer eBooks · doi:10.1007/3-540-36028-x_6 · Cited by 125
“Novel strategies involving transplantation of bone marrow-derived cells or the delivery of molecules capable of stimulating the growth of not only distal capillaries but also of proximal collateral conduit vessels will be required in the future (Chae et al. 2000; Luttun et al. 2002; Cao et al. 2003; Pipp et al. 2003;…”
BackgroundVEGF in Tumor Progression and Targeted Therapy
Chekhonin, V. P., Shein, S. A., Korchagina, A. A., & Gurina, O. I. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990074 · Cited by 102
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12520 · Cited by 107
Pinter, M., Sieghart, W., Reiberger, T., Rohr‐Udilova, N., Ferlitsch, A., & Peck‐Radosavljevic, M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04896.x · Cited by 96
“Several growth factors, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) orchestrate the multiple steps of angiogenesis.(11) The oral multikinase inhibitor sorafenib inhibits cell proliferation and angiogensis by targeting several tyr…”
BackgroundMatriptase activates stromelysin (MMP‐3) and promotes tumor growth and angiogenesis
Jin, X., Yagi, M., Akiyama, N., Hirosaki, T., Higashi, S., Lin, C., Dickson, R. B., Kitamura, H., & Miyazaki, K. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00328.x · Cited by 99
Hemangiosarcoma in Rodents: Mode-of-Action Evaluation and Human Relevance
Cohen, S. M., Storer, R. D., Criswell, K. A., Doerrer, N. G., Dellarco, V. L., Pegg, D. G., Wojcinski, Z. W., Malarkey, D. E., Jacobs, A. C., Klaunig, J. E., et al. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp131 · Cited by 111
“Other factors with a predominantly local action in regulating angiogenic stimuli are platelet-derived growth factor, transforming growth factor b (TGFb), fibroblastderived growth factor (FGF), and hepatocyte growth factor (HGF) (Ferrara and Kerbel, 2005).”
BackgroundInfluentialKuhnert, F., Tam, B. Y. Y., Sennino, B., Gray, J. T., Yuan, J., Jocson, A., Nayak, N. R., Mulligan, R. C., McDonald, D. M., & Kuo, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803194105 · Cited by 103
“VEGF-A signaling constitutes the dominant regulatory pathway for developmental and tumor angiogenesis (2, 3).”
BackgroundTumor angiogenesis and molecular targets for therapy
Cao, Y. (2009) · Frontiers in bioscience · doi:10.2741/3504 · Cited by 104
Vascular Wall as a Reservoir for Different Types of Stem and Progenitor Cells
Ergün, S., Tilki, D., & Klein, D. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3507 · Cited by 109
“Under normal conditions, all components of the vessel wall are mostly quiescent, but in several physiological and pathological processes with new vessel formation via angiogenesis, EC proliferation and migration have been shown (16, 32, 35, 38).”
Baar, J., Silverman, P., Lyons, J. A., Fu, P., Abdul‐Karim, F. W., Ziats, N. P., Wasman, J. K., Hartman, P. H., Jesberger, J. A., Dumadag, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2917 · Cited by 103
Metal-based nanoparticle in cancer treatment: lessons learned and challenges
Hheidari, A., Mohammadi, J., Ghodousi, M., Mahmoodi, M., Ebrahimi, S., Pishbin, E., & Rahdar, A. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1436297 · Cited by 106
Uribe, D. J., Guo, K., Shin, Y.-J., & Sun, D. (2011) · Biochemistry · doi:10.1021/bi101633b · Cited by 96
Maintenance Treatment with Bevacizumab Prolongs Survival in anIn vivoOvarian Cancer Model
Mabuchi, S., Terai, Y., Morishige, K., Tanabe-Kimura, A., Sasaki, H., Kanemura, M., Tsunetoh, S., Tanaka, Y., Sakata, M., Burger, R. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0243 · Cited by 107
Minimally Invasive Approach to the Repair of Injured Skeletal Muscle With a Shape-memory Scaffold
Wang, L., Cao, L., Shansky, J., Wang, Z., Mooney, D., & Vandenburgh, H. (2014) · Molecular Therapy · doi:10.1038/mt.2014.78 · Cited by 95
Pham, E., Birrer, M. J., Eliasof, S., Garmey, E. G., Lazarus, D., Lee, C. R., Man, S., Matulonis, U. A., Peters, C. G., Xu, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2810 · Cited by 95
Self-citationTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 110
“The main signaling tyrosine kinase receptor (TKR) is VEGF-receptor, VEGFR2 (also known as KDR) (Ferrara and Kerbel, 2005).”
BackgroundVizán, P., Sánchez‐Tena, S., Alcarraz‐Vizán, G., Soler, M., Messeguer, R., Pujol, M. D., Lee, W.-N. P., & Cascante, M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp083 · Cited by 99
Microenvironment-feedback regulated hydrogels as living wound healing materials
Cheng, Y., Wang, Y., Wang, Y., Tan, P., Yu, S.-Y., Li, C., Li, Z., Li, Q., Zhou, S., Wang, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60858-3 · Cited by 115
“Upregulation of platelet-derived growth factor receptor beta in OSA-GEL@GC group suggests an increased susceptibility of endothelial cells to platelet-derived growth factor, which is bene fi cial for angiogenesis 62 .”
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.013 · Cited by 100
“However, tumor growth is an even more complex process because during tumor growth, a series of angiogenic and anti-angiogenic factors also shape the tumor phenotype [3].”
BackgroundAntiangiogenic drugs in ovarian cancer
Kumaran, G., Jayson, G. C., & Clamp, A. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604767 · Cited by 99
“Neuropilin expression is increased in ovarian carcinomas (Ferrara and Kerbel, 2005; Osada et al, 2006).”
BackgroundArteriogenesis: basic mechanisms and therapeutic stimulation
Grundmann, S., Piek, J. J., Pasterkamp, G., & Hoefer, I. E. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01861.x · Cited by 102
Kruczynski, A., Poli, M., Dossi, R., Chazottes, E., Berrichon, G., Ricome, C., Giavazzi, R., Hill, B. T., & Taraboletti, G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.019 · Cited by 93
Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
Pircher, A., Hilbe, W., Heidegger, I. M., Drevs, J., Tichelli, A., & Medinger, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12107077 · Cited by 102
“Additionally, the endothelial cells were stimulated by tumor-associated fibroblasts and bone-marrow-derived angiogenic cells (adapted from [23].”
BackgroundRNA sequencing for research and diagnostics in clinical oncology
Buzdin, A., Sorokin, M., Garazha, A., Glusker, A., Aleshin, A., Poddubskaya, E., Sekacheva, M., Kim, E., Gaifullin, N., Giese, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.010 · Cited by 93
Mancino, A., Mancino, M. G., Glaser, S. S., Alpini, G. D., Bolognese, A., Izzo, L., Francis, H., Onori, P., Franchitto, A., Corradini, S. G., et al. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.02.015 · Cited by 92
“Most mportantly, anti-VEGF and anti-angiogenic strategies are urrently under clinical evaluation to delay or stop cancer rogression [6].”
BackgroundCancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Priyadarsini, R. V., & Nagini, S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112798868610 · Cited by 98
Horst, A. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24340 · Cited by 92
Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer
Grisham, R. N., Iyer, G., Sala, E., Zhou, Q. C., Iasonos, A. E., DeLair, D. F., Hyman, D. M., & Aghajanian, C. A. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000190 · Cited by 91
Choi, H., & Moon, A. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1051-1 · Cited by 98
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches
Choi, H. J., Armaiz-Peña, G. N., Pradeep, S., Cho, M. S., Coleman, R. L., & Sood, A. K. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9538-9 · Cited by 97
Autocrine Human Growth Hormone Promotes Tumor Angiogenesis in Mammary Carcinoma
Brunet-Dunand, S. E., Vouyovitch, C. M., Araneda, S., Pandey, V., Vidal, L., Print, C. G., Mertani, H. C., Lobie, P. E., & Perry, J. K. (2008) · Endocrinology · doi:10.1210/en.2008-0608 · Cited by 91
“A number of antiangiogenic molecules aimed at preventing tumor neovascularization or destroying existing tumor vasculature are currently in development (52, 84).”
BackgroundChen, M., Lin, Y., Yang, C., & Hu, M. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100683 · Cited by 92
“Thus, inhibition of angiogenesis presents a promising strategy for cancer treatment [5].”
BackgroundDown regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer
Sun, R., Wu, J., Chen, Y., Lu, M., Zhang, S., Lu, D., & Li, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-225 · Cited by 91
“Notably, THBS1 and THBS2 are special in this family for their type I repeats and both of them are mainly shown as inhibitors of angiogenesis [5,6], one key part of cancer research [7-9].”
BackgroundTortora, G., Bianco, R., Daniele, G., Ciardiello, F., McCubrey, J. A., Ricciardi, M. R., Ciuffreda, L., Cognetti, F., Tafuri, A., & Milella, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.003 · Cited by 104
Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease
Lee, C. G., Ma, B., Takyar, S. S., Ahangari, F., Cruz, C. S. D., He, C. H., & Elias, J. A. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201102-018mw · Cited by 90
Pyriochou, A., Zhou, Z., Koika, V., Petrou, C. C., Cordopatis, P. A., Sessa, W. C., & Papapetropoulos, A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20929 · Cited by 90
“On the other hand, an excessive and deregulated angiogenic response is thought to contribute to cancer, diabetic retinopathy, arthritis, and psoriasis (Carmeliet, 2003; Ferrara and Kerbel, 2005).”
BackgroundAngiogenesis revisited – role and therapeutic potential of targeting endothelial metabolism
Stapor, P. C., Wang, X., Goveia, J., Moens, S., & Carmeliet, P. (2014) · Journal of Cell Science · doi:10.1242/jcs.153908 · Cited by 106
“Endothelial cell metabolism as a target in anti-angiogenesis therapy Traditional anti-angiogenic therapies for cancer aim to starve tumors by inhibiting vascular growth signals, such as VEGF, to cut off their blood supply (Ferrara and Kerbel, 2005; Folkman, 1971).”
BackgroundMiao, H., Hu, K., Jimenez, X., Navarro, E. C., Zhang, H., Lu, D., Ludwig, D. L., Balderes, P. J., & Zhu, Z. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.119 · Cited by 89
Saccone, M. A., Soubeyran, P., Garcia, J., Audebert, S., Camoin, L., Rubis, M., Roques, J., Binétruy, B., Iovanna, J., & Tournaire, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03920-4 · Cited by 104
Functional role of inorganic trace elements in angiogenesis—Part I: N, Fe, Se, P, Au, and Ca
Saghiri, M. A., Asatourian, A., Orangi, J., Sorenson, C. M., & Sheibani, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.010 · Cited by 96
“[6] Ferrara N, Kerbel RS.”
BackgroundSoluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity
Singh, N., Tiem, M., Watkins, R. D., Cho, Y. K., Wang, Y., Olsen, T., Uehara, H., Mamalis, C., Luo, L., Oakey, Z. B., et al. (2013) · Blood · doi:10.1182/blood-2012-08-453043 · Cited by 92
Ye, F., Blackbourn, D. J., Mengel, M., Xie, J., Qian, L., Greene, W., Yeh, I., Graham, D., & Gao, S. (2007) · Journal of Virology · doi:10.1128/jvi.02089-06 · Cited by 89
“Angiogenesis is initiated by the destruction of existing blood vessels and is followed by the sprouting and growth of new blood vessels (22).”
BackgroundSun, J., Jiang, L., Lin, Y., Gerhard, E. M., Jiang, X., Li, L., Yang, J. Y., & Gu, Z. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s122859 · Cited by 89
Recent advances in anti-angiogenic nanomedicines for cancer therapy
Bhattarai, P., Hameed, S., & Dai, Z. (2018) · Nanoscale · doi:10.1039/c7nr09612g · Cited by 92
Kontovinis, L., Papazisis, K. T., Touplikioti, P., Andreadis, C. B., Mouratidou, D., & Kortsaris, A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-82 · Cited by 88
“VHL – HIF-1 – VEGF pathway is therefore deregulated in RCC and it represents a reasonable therapeutic target for renal cell carcinoma [12].”
BackgroundMutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice
Koga, M., Kai, H., Egami, K., Murohara, T., Ikeda, A., Yasuoka, S., Egashira, K., Matsuishi, T., Kai, M., Kataoka, Y., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.182 · Cited by 88
Osawa, T., Tsuchida, R., Muramatsu, M., Shimamura, T., Wang, F., Suehiro, J., Kanki, Y., Wada, Y., Yuasa, Y., Aburatani, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3231 · Cited by 99
“Introduction Angiogenesis is essential for tumor growth and metastasis (1, 2).”
BackgroundNisancioglu, M. H., Betsholtz, C., & Genové, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4245 · Cited by 87
“The idea of targeting angiogenesis to treat tumors was proposed almost 40 years ago (1), and since then, several approaches to block or disrupt tumor angiogenesis have been explored (2).”
BackgroundNanoparticles‐Mediated Combination Therapies for Cancer Treatment
Shrestha, B., Tang, L., & Romero, G. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900076 · Cited by 98
Molecular ultrasound assessment of tumor angiogenesis
Deshpande, N., Pysz, M. A., & Willmann, J. K. (2010) · Angiogenesis · doi:10.1007/s10456-010-9175-z · Cited by 90
“, an antibody or small molecule inhibitor of new vessel formation [6, 8], or anti-vascular therapy e.”
Koch, M., Hussein, F., Woeste, A., Gründker, C., Frontzek, K., Emons, G., & Hawighorst, T. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1085-7 · Cited by 88
“There is large amount of evidence that tumor growth is dependent on angiogenesis [8, 15, 16].”
BackgroundBridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Anti-angiogenesis in cancer therapeutics: the magic bullet
Oguntade, A. S., Al-Amodi, F., Alrumayh, A., Alobaida, M., & Bwalya, M. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00072-6 · Cited by 99
Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis
Dong, F., Zhou, X., Li, C., Yan, S., Deng, X., Cao, Z., Li, L., Tang, B., Allen, T. D., & Liu, J. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955728 · Cited by 85
“Therefore, angiogenesis inhibitors could be clinically useful for the treatment of cancer as well as other diseases dependent on new blood vessel formation.(3,4) A number of growth factors have been implicated in the control of angiogenesis but vascular endothelial growth factor (VEGF) is a major regulator of angiogen…”
BackgroundMesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy
Sun, J., Jiang, Q. L., Zhang, X., Shan, K., Liu, B.-H., Zhao, C., & Yan, B. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s195504 · Cited by 87
Tooth Slice–Based Models for the Study of Human Dental Pulp Angiogenesis
Gonçalves, S. B., Dong, Z., Bramante, C. M., Holland, G. R., Smith, A. J., & Nor, J. E. (2007) · Journal of Endodontics · doi:10.1016/j.joen.2007.03.012 · Cited by 87
Tie2-expressing monocytes (TEMs): Novel targets and vehicles of anticancer therapy?
Palma, M. D., & Naldini, L. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.04.001 · Cited by 96
Modulation of angiogenesis by dithiolethione‐modified NSAIDs and valproic acid
Isenberg, J. S., Jia, Y., Field, L., Ridnour, L. A., Sparatore, A., Soldato, P. D., Sowers, A. L., Yeh, G. C., Moody, T. W., Wink, D. A., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707198 · Cited by 93
“Under nonpathological conditions, it is a tightly regulated process representing a balance between stimulating and inhibiting factors (Ferrara and Kerbel, 2005).”
BackgroundVEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle
Gabhann, F. M., Ji, J. W., & Popel, A. S. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00800.2006 · Cited by 95
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.